Molecular Partners AG

Equities

MOLN

CH0256379097

Biotechnology & Medical Research

We are working hard...
  • We are working hard to come back as soon as possible.
  • Nous travaillons dur pour revenir au plus vite.
  • Wir arbeiten hart daran, so schnell wie möglich zurückzukommen
  • Estamos trabajando duro para volver lo antes posible.
  • Stiamo lavorando sodo per tornare il prima possibile.
  • Wij werken hard om zo snel mogelijk weer terug te zijn.
503 Backend fetch failed

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
Molecular Partners Swings to Loss in FY23; Revenue Down MT
Molecular Partners AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
US Court Dismisses Putative Class Action Against Molecular Partners MT
Transcript : Molecular Partners AG Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Molecular Partners Gears Up for 2024 Milestones, Including Data From Leukemia Treatment Trial MT
Molecular Partners, Orano Med Team Up to Develop Radio-DARPin Therapeutics Against Cancer MT
Molecular Partners AG and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies CI
Novocure Names Nicolas Leupin as Chief Medical Officer MT
ADRs Advance; Boqii Holding Ltd. Climbs 16.2% DJ
ADRs Hold Steady; TDCX Inc. Climbs 30.4% DJ
Molecular Partners Reports 'Encouraging' Initial Data From Phase 1/2a Trial of MP0533 MT
Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting CI
JPMorgan Cuts Molecular Partners Price Target to $4.50 From $6.60, Maintains Neutral Rating MT
Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting CI
Molecular Partners Says Preliminary Data From MP0533's Phase 1/2a Trial Show 'Acceptable Safety Profile' MT
Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition CI
Molecular Partners AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Molecular Partners AG(SWX:MOLN) dropped from S&P Global BMI Index CI
Transcript : Molecular Partners AG, H1 2023 Earnings Call, Aug 25, 2023
Molecular Partners' Chief Medical Officer to Step Down; Interim Successor Named MT
Molecular Partners Turns to Loss in H1; Revenue Slides Down MT
Molecular Partners AG Announces Executive Changes CI
Molecular Partners AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Molecular Partners AG Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Molecular Partners AG
More charts
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.375 CHF
Average target price
9.5 CHF
Spread / Average Target
+181.48%
Consensus

Quarterly revenue - Rate of surprise

We are working hard...
  • We are working hard to come back as soon as possible.
  • Nous travaillons dur pour revenir au plus vite.
  • Wir arbeiten hart daran, so schnell wie möglich zurückzukommen
  • Estamos trabajando duro para volver lo antes posible.
  • Stiamo lavorando sodo per tornare il prima possibile.
  • Wij werken hard om zo snel mogelijk weer terug te zijn.
503 Backend fetch failed
  1. Stock Market
  2. Equities
  3. MOLN Stock
  4. News Molecular Partners AG
  5. Molecular Partners : Says Preclinical Data Show Ensovibep's Potency Against COVID-19 Viral Variants